Efficacy of equol for endothelial function of menopausal woman

Efficacy of equol for endothelial function of menopausal patients with coronary artery disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200115

Enrollment

100

Registered

2020-09-11

Start date

2020-09-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease coronary artery disease, endothelial function

Interventions

administration arm: a 10 mg of equol is given daily for 3 months non-administration arm: none of equol adoministration

equol, FMD, Endo-PAT

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Menopausal female patients with coronary artery disease under 75s

Exclusion criteria

Exclusion criteria: 1) Acute coronary syndrome concomitant with cardiogenic shock or severe congestive heart failure 2) Administration of antibiotics within a month 3) Soy-bean allergy 4) Complication of infection or inflammatory disease 5) Neoplasm 6) Equol administration 7) Estrogen and/or progesterone administration 8) Hemodialysis 9) Attending physician's decision

Design outcomes

Primary

Measure	Time frame
FMD	—

Secondary

Measure	Time frame
RH-PAT	—

Contacts

Public ContactShichiro Abe

Dokkyo Medical University Hospital

abenana@dokkyomed.ac.jp+81-282-87-2146

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026